JPMorgan analysts project that the rise of these weight-loss drugs could strip between $30 billion and $55 billion from annual food and beverage revenue by 2030. Many users are already scaling back their restaurant visits, according to data from the National Restaurant Association. To counter this, Burger King is exploring smaller, protein-dense alternatives like Whopper Bites and custom bowls, aiming to capture customers who seek fast options without the traditional caloric density.
Burger King Prepares for Shrinking Appetites Driven by GLP-1 Drugs
With 11% of U.S. adults now using GLP-1 medications, the fast-food industry faces a structural shift in consumer demand. Tom Curtis, president of Burger King for the U.S. and Canada, acknowledges the trend is poised to alter dining habits, forcing major chains to rethink portions and menu compositions to remain relevant.
Despite the long-term pressure, the company is not abandoning its core identity. Whopper sales remain a primary revenue driver, and recent results suggest that broader turnaround efforts are gaining momentum. Under the $2 billion “Reclaim the Flame” strategy, the chain reported a 5.8% increase in same-store sales last quarter, marking a sharp recovery from the previous year’s decline.
Comments (0)
No comments yet. Be the first!